Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 05, 2023

Tixagevimab and Cilgavimab Use in Patients With MS and NMOSD During Anti-CD20 Treatment

Journal of Neuroimmunology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Neuroimmunology
Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience
J. Neuroimmunol. 2023 Sep 13;383(xx)578199, S Gelibter, F Pirro, L Saraceno, E Susani, MC Moioli, M Puoti, EC Agostoni, A Protti

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading